Cargando…

N-Terminally Truncated and Pyroglutamate-Modified Aβ Forms Are Measurable in Human Cerebrospinal Fluid and Are Potential Markers of Disease Progression in Alzheimer’s Disease

Alzheimer’s disease (AD) is a pathology characterized by the accumulation in the brain of intracellular and extracellular amyloid-β (Aβ) aggregates, especially of Aβ1–40 and Aβ1–42 peptides. It is known that N-terminally truncated or modified Aβ forms also exist in AD brains and cerebrospinal fluid...

Descripción completa

Detalles Bibliográficos
Autores principales:	Domingo, Guido, Benussi, Luisa, Saraceno, Claudia, Bertuzzi, Michela, Nicsanu, Roland, Longobardi, Antonio, Bellini, Sonia, Cagnotto, Alfredo, Salmona, Mario, Binetti, Giuliano, Ghidoni, Roberta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8358181/ https://www.ncbi.nlm.nih.gov/pubmed/34393717 http://dx.doi.org/10.3389/fnins.2021.708119

Ejemplares similares

Cerebrospinal Fluid EV Concentration and Size Are Altered in Alzheimer’s Disease and Dementia with Lewy Bodies
por: Longobardi, Antonio, et al.
Publicado: (2022)

Plasma Extracellular Vesicle Size and Concentration Are Altered in Alzheimer’s Disease, Dementia With Lewy Bodies, and Frontotemporal Dementia
por: Longobardi, Antonio, et al.
Publicado: (2021)

Increased Serum Beta-Secretase 1 Activity is an Early Marker of Alzheimer’s Disease
por: Nicsanu, Roland, et al.
Publicado: (2022)

Plasma Small Extracellular Vesicle Cathepsin D Dysregulation in GRN/C9orf72 and Sporadic Frontotemporal Lobar Degeneration
por: Bellini, Sonia, et al.
Publicado: (2022)

The PINK1 p.Asn521Thr Variant Is Associated with Earlier Disease Onset in GRN/C9orf72 Frontotemporal Lobar Degeneration
por: Rossi, Giacomina, et al.
Publicado: (2022)

Investigating the Endo-Lysosomal System in Major Neurocognitive Disorders Due to Alzheimer’s Disease, Frontotemporal Lobar Degeneration and Lewy Body Disease: Evidence for SORL1 as a Cross-Disease Gene
por: Benussi, Luisa, et al.
Publicado: (2021)

Plasma Small Extracellular Vesicles with Complement Alterations in GRN/C9orf72 and Sporadic Frontotemporal Lobar Degeneration
por: Bellini, Sonia, et al.
Publicado: (2022)

A Window into the Heterogeneity of Human Cerebrospinal Fluid Aβ Peptides
por: Ghidoni, Roberta, et al.
Publicado: (2011)

Loss of Neuroprotective Factors in Neurodegenerative Dementias: The End or the Starting Point?
por: Benussi, Luisa, et al.
Publicado: (2017)

Pathological 25 kDa C-Terminal Fragments of TDP-43 Are Present in Lymphoblastoid Cell Lines and Extracellular Vesicles from Patients Affected by Frontotemporal Lobar Degeneration and Neuronal Ceroidolipofuscinosis Carrying a GRN Mutation
por: Cimini, Sara, et al.
Publicado: (2022)

Synergistic Effect on Neurodegeneration by N-Truncated Aβ(4−42) and Pyroglutamate Aβ(3−42) in a Mouse Model of Alzheimer's Disease
por: Lopez-Noguerola, Jose S., et al.
Publicado: (2018)

Rac1 activation links tau hyperphosphorylation and Aβ dysmetabolism in Alzheimer’s disease
por: Borin, Mirta, et al.
Publicado: (2018)

Pyroglutamate and Isoaspartate modified Amyloid-Beta in ageing and Alzheimer’s disease
por: Moro, Maria Luisa, et al.
Publicado: (2018)

Pyroglutamate Aβ cascade as drug target in Alzheimer’s disease
por: Bayer, Thomas A.
Publicado: (2021)

Progranulin Mutations Affects Brain Oscillatory Activity in Fronto-Temporal Dementia
por: Moretti, Davide V., et al.
Publicado: (2016)

Enhanced accumulation of N-terminally truncated Aβ with and without pyroglutamate-11 modification in parvalbumin-expressing GABAergic neurons in idiopathic and dup15q11.2-q13 autism
por: Frackowiak, Janusz, et al.
Publicado: (2020)

Metabolic Acidosis Due To Pyroglutamic Acid
por: Serpa, Maria João, et al.
Publicado: (2018)

Flucloxacillin and paracetamol induced pyroglutamic acidosis
por: Zand Irani, Anis, et al.
Publicado: (2021)

Alzheimer therapy with an antibody against N-terminal Abeta 4-X and pyroglutamate Abeta 3-X
por: Antonios, Gregory, et al.
Publicado: (2015)

N-terminal pyroglutamate formation in CX3CL1 is essential for its full biologic activity
por: Kehlen, Astrid, et al.
Publicado: (2017)

Regulatory miRNAs in Cardiovascular and Alzheimer’s Disease: A Focus on Copper
por: Sacco, Anna, et al.
Publicado: (2022)

Pyroglutamate-Modified Amyloid Beta Peptides: Emerging Targets for Alzheimer´s Disease Immunotherapy
por: Perez-Garmendia, Roxanna, et al.
Publicado: (2013)

Exploring Neurofilament Light Chain and Exosomes in the Genetic Forms of Frontotemporal Dementia
por: Zanardini, Roberta, et al.
Publicado: (2022)

Copper Imbalance in Alzheimer’s Disease: Meta-Analysis of Serum, Plasma, and Brain Specimens, and Replication Study Evaluating ATP7B Gene Variants
por: Squitti, Rosanna, et al.
Publicado: (2021)

Novel Vaccine against Pathological Pyroglutamate-Modified Amyloid Beta for Prevention of Alzheimer’s Disease
por: Zagorski, Karen, et al.
Publicado: (2023)

The Missing Heritability of Sporadic Frontotemporal Dementia: New Insights from Rare Variants in Neurodegenerative Candidate Genes
por: Ciani, Miriam, et al.
Publicado: (2019)

4,4′-Bipyridine–pyroglutamic acid (1/2)
por: Arman, Hadi D., et al.
Publicado: (2009)

Pyroglutamic Acidosis – An Underrecognised Entity Associated with Acetaminophen Use
por: Ng, Wincy Wing-Sze, et al.
Publicado: (2023)

Purification and Characterization of Recombinant N-Terminally Pyroglutamate-Modified Amyloid-β Variants and Structural Analysis by Solution NMR Spectroscopy
por: Dammers, Christina, et al.
Publicado: (2015)

Long‐term patterns of urinary pyroglutamic acid in healthy humans
por: Lord, Richard S.
Publicado: (2016)

The Bacteroidetes Q-Rule: Pyroglutamate in Signal Peptidase I Substrates
por: Bochtler, Matthias, et al.
Publicado: (2018)

5-oxoprolinuria (Pyroglutamic Aciduria) and Metabolic Acidosis: Unraveling the Mystery
por: Senthilkumaran, Subramanian, et al.
Publicado: (2019)

Immunotherapy targeting pyroglutamate-3 Aβ: prospects and challenges
por: Cynis, Holger, et al.
Publicado: (2016)

Plasma pyroglutamate‐modified amyloid beta differentiates amyloid pathology
por: Wang, Pei‐Ning, et al.
Publicado: (2020)

Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer’s disease cases
por: Wirths, Oliver, et al.
Publicado: (2009)

N-Terminal Truncated UCH-L1 Prevents Parkinson's Disease Associated Damage
por: Kim, Hee-Jung, et al.
Publicado: (2014)

C-terminal α-synuclein truncations are linked to cysteine cathepsin activity in Parkinson's disease
por: McGlinchey, Ryan P., et al.
Publicado: (2019)

An unusual cause of high anion gap metabolic acidosis: pyroglutamic acidosis
por: Wardell, RJ, et al.
Publicado: (2012)

Pyroglutamic acidosis by glutathione regeneration blockage in critical patients with septic shock
por: Gamarra, Yenifer, et al.
Publicado: (2019)

Acquired pyroglutamic acidosis due to long-term dicloxacillin and paracetamol use
por: Zand Irani, Anis, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_rl7sfr06r8im01vrnhb09iieeh